Abstract:Background: The treatment of lung adenocarcinoma (LUAD) has been stuck in a bottleneck due to a number of factors. There is a pressing need for research into potential genetic markers to help drug development and improve the prognosis of patients. SLC2A1 has been reported in multiple LUAD-related prognosis prediction signatures. However, the role of SLC2A1 in the occurrence and development of WAD and its impact on prognosis remain elusive. Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were used to acquire the samples. We used R to perform statistical analysis, Gene Set Enrichment Analysis (GSEA), immune infiltration and immune cell correlation analysis, drug sensitivity analysis, and visualization. The immune cell score was calculated using the Timer2.0 database. Prognostic analysis was performed using R, Gene Expression Profiling Interactive Analysis (GEPIA), and the Kaplan-Meier Plotter. Overall survival and progression free survival were the main outcome of prognosis analysis. Protein-protein interaction, disease-genetics analysis, and tissue-specific enrichment analyses were performed using Metascape. Results: SLC2A1 was highly expressed in LUAD tissues. Univariate COX regression [hazard ratio (HR) = 1.689, 95% confidence interval (CI): 1.242-2.249, P<0.001] and multivariate COX regression including age, gender, smoking, TNM stage and SLC2A1 expression (HR = 1.567, 95% CI: 1.127-2.179, P=0.008) showed that SLC2A1 was an independent prognostic risk factor for LUAD. GSEA and Metascape analysis showed that SLC2A1 was strongly associated with the cell cycle, mitosis, lung tissue, and tumor recurrence. Immune correlation analysis showed that SLC2A1 was associated with two tumor infiltration immune cells: activated CD (cluster of differentiation)4* memory T cells (r=0.31, P=0.003) and activated mast cells (r=-0.28, P=0.010). Moreover, patients with high SLC2A1 expression had higher immune checkpoint molecules and Tumor Immune Dysfunction and Exclusion (TIDE) scores, indicating poorer immunotherapy efficacy. Patients with high SLC2A1 expression were more sensitive to chemotherapy drugs and less sensitive to targeted drugs compared to those with low SLC2A1 expression. Conclusions: The high expression of SLC2A1 in LUAD predicted poor prognosis and was closely related to tumor immunity, which could be used as an effective prognostic biomarker to provide a new strategy for clinical prognosis assessment and immunotherapy for LUAD.

Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

TKI Resistant-Based Prognostic Immune Related Gene Signature in LUAD, in Which FSCN1 Contributes to Tumor Progression.

Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma

Development of Cancer-Associated Fibroblast-Related Gene Signature for Predicting the Survival and Immunotherapy Response in Lung Adenocarcinoma.

A novel gene signature related to focal adhesions for distinguishing and predicting the prognosis of lung squamous cell carcinoma

Elevated FUS/TLS Expression is Negatively Associated with E-cadherin Expression and Prognosis of Patients with Non-Small Cell Lung Cancer

High CTSL2 expression predicts poor prognosis in patients with lung adenocarcinoma

A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma

Comprehensive Analyses of a CD8+ T Cell Infiltration Related Gene Signature with Regard to the Prediction of Prognosis and Immunotherapy Response in Lung Squamous Cell Carcinoma

Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma

Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer

Comprehensive Analysis of a Novel Immune-Related Gene Signature in Lung Adenocarcinoma

Reduced expression of cathepsin F predicts poor prognosis in patients with clear cell renal cell carcinoma

Integrated Bioinformatics Analysis Reveals That the Expression of Cathepsin S is Associated with Lymph Node Metastasis and Poor Prognosis in Papillary Thyroid Cancer

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.

SLC2A1 Plays a Significant Prognostic Role in Lung Adenocarcinoma and is Associated with Tumor Immunity Based on Bioinformatics Analysis.

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma

Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients

A Bioinformatics-Based Analysis of an Cuproptosis and Ferroptosis-Related Gene Signature Predicts the Prognosis of Patients with Lung Adenocarcinoma